[11 June 2013]
Products Affected - Description
Promethazine injection, West-Ward
50 mg/mL 1 mL ampule (NDC 00641-1496-35)
50 mg/mL 1 mL vial (NDC 00641-0929-25)
50 mg/mL 1 mL Novaplus vial (NDC 00641-0956-25)
Phenergan injection, West-Ward
50 mg/mL 1 mL vial (NDC 00641-6085-25)
Promethazine injection, Hospira
25 mg/mL 1 mL Carpuject syringe (NDC 00409-2312-31)
25 mg/mL 1 mL iSecure syringe (NDC 00409-2312-02) - discontinued
Promethazine injection, Teva
25 mg/mL 1 mL vial (NDC 00703-2191-04)
50 mg/mL 1 mL vial (NDC 00703-2201-04)
Reason for the Shortage
- Teva states the shortage is due to manufacturing delays.
- West-Ward states the shortage is due to manufacturing delays. The company has also changed the NDC numbers for products that were formerly Baxter products.
- Hospira has promethazine products on back order due to supply interruption. Hospira discontinued promethazine 25mg/mL 1 mL iSecure syringe in September 2011.
Available Products
Promethazine injection, West-Ward
25 mg/mL 1 mL vial (NDC 00641-0928-25)
25 mg/mL 1 mL ampule (NDC 00641-1495-35)
25 mg/mL 1 mL Novaplus ampule (NDC 00641-0948-35)
25 mg/mL 1 mL Novaplus vial (NDC 00641-0955-25)
50 mg/mL 1 mL Novaplus ampule (NDC 00641-0949-35)
Phenergan injection, West-Ward
25 mg/mL 1 mL vial (NDC 00641-6084-25)
25 mg/mL 1 mL ampule (NDC 00641-6082-25)
50 mg/mL 1 mL ampule (NDC 00641-6083-25)
Promethazine injection, X-Gen
25 mg/mL 1 mL ampule (NDC 39822-5500-03)
50 mg/mL 1 mL ampule (NDC 39822-5500-06)
Estimated Resupply Dates
- West-Ward (formerly Baxter) has promethazine 50 mg/mL 1 mL vials and 1 mL ampules on back order and the company estimates a release date of early-July 2013 for the 1 mL ampules and late-June 2013 for the 1 mL vials. The 50 mg/mL 1 mL Novaplus vials are also on back order and the company cannot estimate a release date.
- West-Ward has Phenergan injection 50 mg/mL 1 mL vials on back order, and the company estimates a release date in late-June 2013.
- Hospira has promethazine 25 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date in 2013.
- Teva has all promethazine injection presentations on back order and the company cannot estimate a release date.
Related Shortages
Updated
June 11, 2013; April 30, 2013; March 26, 2013; March 6, 2013; February 20, 2013; February 13, 2013; January 30, 2013; January 25, 2013; January 18, 2013; November 28, 2012; November 9, 2012; September 7, 2012; August 13, 2012; July 20, 2012; June 21, 2012; May 7, 2012; March 21, 2012; March 9, 2012; February 10, 2012; January 24, 2012; January 6, 2012; December 9, 2011; November 30, 2011; November 23, 2011; November 9, 2011; September 6, 2011; July 15, 2011; May 24, 2011; April 6, 2011; March 18, 2011; March 1, 2011; February 9, 2011; January 27, 2011; December 15, 2010; December 1, 2010; November 4, 2010; October 14, 2010; October 1, 2010; September 9, 2010; August 31, 2010; August 18, 2010; July 30, 2010; June 22, 2010, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins